Dental Care Clinics in Orinda, CA Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Sumeet Sandhu Dds Inc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 93 Moraga Way Ste 201, Orinda, CA 94563 Phone: 925-253-0165 |
Baljit Dhillon Dds Inc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 93 Moraga Way Ste 201, Orinda, CA 94563 Phone: 925-253-0165 |
Min-jeong Kim Dds Ms Inc Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 5 Santa Maria Way, Orinda, CA 94563 Phone: 925-254-2133 |
Orinda Dental Care Dental Practice Of Dr. Morgan Mehranfard Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 8 Camino Encinas Ste 110, Orinda, CA 94563 Phone: 925-254-3725 |
Samadian Inc Dentist Medicare: Not Enrolled in Medicare Practice Location: 23 Orinda Way Ste 301, Orinda, CA 94563 Phone: 925-254-2360 Fax: 925-254-7392 |
News Archive
Trial of new type of drug that attacks amyloid
Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer's disease patients.
Be a Hero For Babies Day raises more than $2.65M to support March of Dimes programs
With local telethons, carwashes, golf outings, pancake breakfasts, pie-throwing contests and a television partnership, Farmers Insurance Group and its agents nationwide led their communities to raise more than $2.65 million in a one-day fundraiser, Be a Hero for Babies Day, on July 22 to support March of Dimes programs to give every baby a healthy start in life.
Occlutech announces favorable ruling in patent litigation with St Jude-AGA Medical
Occlutech, a leading European developer of septum occluders such as PFO and ASD devices as well as other innovative, minimally invasive cardiac implants, today announced that it got a favorable ruling in patent litigation with St Jude-AGA Medical from the District Court of Milan in Italy.
KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors
KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
› Verified 4 days ago